Market Newsdesk

Magnite to Announce Fourth Quarter 2020 Financial Results on February 24, 2021

LOS ANGELES–(BUSINESS WIRE)–
Magnite (Nasdaq: MGNI), the largest independent sell-side advertising platform, will announce its financial results for the quarter ended December 31, 2020 after the market close on Wednesday, February 24, 2021. The Company will host a conference call at 1:30 PM (PT) / 4:30 PM (ET) the same day to discuss its financial results and outlook.

Live conference call
Toll free number:			(844) 875-6911 (for domestic callers)
Direct dial number:			(412) 902-6511 (for international callers)
Passcode:			Ask to join the Magnite conference call
Simultaneous audio webcast			http://investor.magnite.com, under “Events and Presentations”
Conference call replay
Toll Free number:			(877) 344-7529 (for domestic callers)
Direct dial number:			(412) 317-0088 (for international callers)
Passcode:			10151407
Webcast link:			http://investor.magnite.com, under “Events and Presentations”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising platform that combines Rubicon Project’s programmatic expertise with Telaria’s leadership in CTV. Publishers use our technology to monetize their content across all screens and formats—including desktop, mobile, audio and CTV. And the world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in sunny Los Angeles, bustling New York City, historic London, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM and APAC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005269/en/

Investor Relations:

Nick Kormeluk, 949-500-0003

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Entertainment Other Technology Advertising Online Communications Mobile Entertainment TV and Radio Internet

MEDIA:

Posted on January 21, 2021 8:03 am

EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of ‘EuCorVac-19’ in Korea

EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of ‘EuCorVac-19’ in Korea

– Starting the Phase I/II trial in Eunpyeong St. Mary’s Hospital

SEOUL, South Korea–(BUSINESS WIRE)–EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005311/en/

EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. (Photo: Business Wire)

The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity.

EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals.

A company official said, “EuCorVac-19 is designed to induce a rapid antibody response, a high level of neutralizing antibody and excellent cellular immune response by combining both SNAP technology of POP Biotechnologies that EuBiologics has invested and EulMT in-licensed from Korea Institute of Science and Technology. EuCorVac-19 has demonstrated superior immune response against SARS-CoV-2 in the animal model, therefore, we expect to see the safety, tolerance and immunogenicity demonstrated in the Phase I/II trials.”

EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005311/en/

EuBiologics Co., Ltd.

Tae Young Jin

+82-70-4881-7117

[email protected]

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Other Manufacturing Research Infectious Diseases Hospitals Clinical Trials Manufacturing Biotechnology Pharmaceutical Health Science

MEDIA:

Photo

EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. (Photo: Business Wire)

Logo

American Eagle Outfitters Announces Its Real Power. Real Growth. Plan

Plan targets $5.5 billion in revenue; 10% operating margin; and $550 million in operating income — a 15% CAGR through 2023

Doubles Aerie revenue to $2 billion

Reignites American Eagle for profit growth

PITTSBURGH–(BUSINESS WIRE)–
American Eagle Outfitters, Inc. (NYSE: AEO) will today host a virtual investor meeting to present its “Real Power. Real Growth.” value creation plan and unveil its long-term financial outlook. To achieve these goals, AEO has the following strategic priorities:

• Double Aerie to $2 billion in revenue;
• Reignite American Eagle for profit growth

As part of the plan, the company will leverage customer-focused capabilities and continue to strengthen its ROI discipline, while building on the power of AEO’s people, culture and purpose.

“2020 demonstrated the strength of our organization, our brands and our capabilities – and we are emerging with momentum. As the pace of change and innovation accelerated over the past year, I believe the environment is ripe with potential, and I see more opportunity for AEO than ever before. Today, I am pleased to provide greater transparency to our leading brands, our strategies and our long-term financial targets, aimed at creating lasting value for shareholders,” commented Jay Schottenstein, AEO’s Executive Chairman of the Board and Chief Executive Officer.

Long-Term Financial Outlook

AEO targets revenue of approximately $5.5 billion and operating income of $550 million in fiscal 2023, with the operating margin expanding to 10%. These targets exclude potential asset impairment and restructuring charges.

Aerie revenue is expected to grow at a mid-20%’s compound annual growth rate to approximately $2 billion, providing significant profit flow through. American Eagle revenue is expected to remain roughly flat to fiscal 2019, at approximately $3.5 billion, with improved profitability.

This morning, AEO also filed a Form 8-K with the Securities and Exchange Commission (SEC) that provides greater transparency to American Eagle and Aerie’s historical financial performance. Going forward, the Company has elected to disaggregate the results of its American Eagle brand and Aerie brand operating segments, which have historically been aggregated and presented as one reportable segment.

The virtual investor meeting will begin at 11am Eastern Time and feature presentations and a question-and-answer session with members of the company’s executive leadership team. The event can be accessed in the Investor Relations section on AEO’s website, www.aeo-inc.com. A replay of the investor meeting will be archived and made available online on the company’s website.

# # #

About American Eagle Outfitters, Inc.

American Eagle Outfitters, Inc. (NYSE: AEO) is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices under its American Eagle® and Aerie® brands. Our purpose is to show the world that there’s REAL power in the optimism of youth. The company operates stores in the United States, Canada, Mexico, and Hong Kong, and ships to 81 countries worldwide through its websites. American Eagle and Aerie merchandise also is available at more than 200 international locations operated by licensees in 25 countries. For more information, please visit www.aeo-inc.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release and related statements by management contain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), which represent our expectations or beliefs concerning future events, including our long-term financial outlook. All forward-looking statements made by the company involve material risks and uncertainties and are subject to change based on many important factors, some of which may be beyond the company’s control. Words such as “estimate,” “project,” “plan,” “believe,” “expect,” “anticipate,” “intend,” “potential,” and similar expressions may identify forward-looking statements. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise and even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. The following factors, in addition to the risks disclosed in Item 1A., Risk Factors, of our Annual Report on Form 10-K for the fiscal year ended February 1, 2020 and in our Quarterly Reports on Form 10-Q for the fiscal quarters ended May 2, 2020, August 1, 2020, and October 31, 2020, and in any other filings that we may make with the Securities and Exchange Commission in some cases have affected, and in the future could affect, the company’s financial performance and could cause actual results for the fourth quarter 2020 and beyond to differ materially from those expressed or implied in any of the forward-looking statements included in this release or otherwise made by management: the negative impacts of the COVID-19 pandemic and related operational disruptions; the risk that the company’s operating, financial and capital plans may not be achieved; our inability to anticipate customer demand and changing fashion trends and to manage our inventory commensurately; seasonality of our business; our inability to achieve planned store financial performance; our inability to react to raw material cost, labor and energy cost increases; our inability to gain market share in the face of declining shopping center traffic; our inability to respond to changes in e-commerce and leverage omni-channel demands; our inability to expand internationally; difficulty with our international merchandise sourcing strategies; challenges with information technology systems, including safeguarding against security breaches; and global economic, public health, social, political and financial conditions, and the resulting impact on consumer confidence and consumer spending, as well as other changes in consumer discretionary spending habits, which could have a material adverse effect on our business, results of operations and liquidity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005152/en/

Olivia Messina

412-432-3300

[email protected]

Sarah Gordon

SHADOW

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Women Teens Men Specialty Children Consumer Fashion Retail

MEDIA:

Logo

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

Company Expects to Release Topline Data at the Symposium on Advanced Wound Care—Spring 2021

SALT LAKE CITY–(BUSINESS WIRE)–PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 100 subjects in a randomized controlled trial (RCT) evaluating SkinTE® plus standard of care (SOC) versus SOC alone for the treatment of diabetic foot ulcers (DFUs). PolarityTE plans to report topline data via press release and presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2021 to be held May 12-16, 2021, barring any unforeseen scheduling or other disruptions due to COVID-19. Details for the SAWC 2021 Virtual Conference can be found at https://www.sawcspring.com/.

The primary endpoint of this Diabetic Foot Ulcer Trial (NCT03881254) is a comparison of the percent of index ulcers closed at 12 weeks, and additional details regarding the trial can be found at https://clinicaltrials.gov/ct2/show/study/NCT03881254.

David Seaburg, Chief Executive Officer, commented, “The completion of target enrollment for this DFU RCT is an important milestone for PTE and a step toward building what we believe will be additional scientific evidence to support the potential benefits SkinTE may offer patients suffering from debilitating diabetic foot ulcers.”

Nik Sopko, MD, PhD, Chief Scientific Officer, commented, “Enrollment completion of this trial in the midst of a global pandemic highlights the tremendous efforts by trial investigators and a dedicated PolarityTE team. We are incredibly grateful to all of the patients who participated in this study and look forward to presenting the results.”

About PolarityTE®

PolarityTE is focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient’s own tissue and uses the patient’s own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic, and self-propagating product designed to regenerate the target tissues. PolarityTE’s innovative methods are intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.

Forward Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to the impact of the COVID-19 pandemic and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005140/en/

Investors:

Rich Haerle

VP, Investor Relations

PolarityTE, Inc.

[email protected]

(385) 315-0697

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Health Diabetes Surgery Stem Cells Clinical Trials Biotechnology

MEDIA:

Logo

KB Home Announces the Grand Opening of Willow Wood Place, a New-Home Community in North Houston Priced From the $210,000s

Homebuilder’s new community offers personalized homes in a desirable Houston location.

HOUSTON–(BUSINESS WIRE)–
KB Home (NYSE: KBH) today announced the grand opening of Willow Wood Place, a new single-family home community in North Houston. Willow Wood Place’s location near Highway 249 offers easy access to Grand Parkway 99 and Beltway 8 for an easy commute to several major employment centers, including The Woodlands, Northwest Crossing and downtown Houston. The community is minutes to a wide variety of entertainment and recreation venues, including Longwood Golf Club, Matzke Park, iT’Z^® Houston Family Food & Fun, Sam Houston Race Park and The Cynthia Woods Mitchell Pavilion. Residents will also enjoy nearby shopping at Tomball Crossing, Louetta Shopping Center and Vintage Park Shopping Village.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005112/en/

The homes at Willow Wood Place showcase popular design characteristics like spacious lofts, gourmet kitchens overlooking expansive great rooms, and master suites with walk-in closets. The community offers one- and two-story floor plans that feature up to five bedrooms and three baths, and range in size from approximately 1,200 to 2,600 square feet. Future community amenities include a park, playground and open green space.

“Willow Wood Place’s desirable location provides easy access to major roadways for a short commute to major employment centers throughout the region,” said Brett Dietz, President of KB Home’s Houston division. “The new community is also situated within the Tomball Independent School District, and all zoned schools are less than two miles away. As with other KB Home communities, Willow Wood Place provides home shoppers the opportunity to purchase a new KB home that can be personalized to reflect their lifestyle and needs.”

KB Home stands out from other homebuilders as the company gives homebuyers exceptional choice and control. KB Home starts by offering a wide variety of homes at an affordable price. From there, the builder gives buyers the ability to personalize their homes from homesites and floor plans to design features. The KB Home team works hand in hand with homeowners every step of the way so they have a real partner in the process.

Every KB home is designed to be ENERGY STAR^® certified thanks to the quality construction techniques and materials utilized that ultimately deliver significant savings on utility bills compared to used homes. Additionally, all new KB homes are designed to deliver an enhanced indoor environment and include high performance ventilation systems, low- or zero-VOC products and other features guided by the Environmental Protection Agency’s (EPA) Indoor airPLUS standards.

The Willow Wood Place sales office and model homes are open for private in-person tours by appointment, and walk-in visits are welcome. Homebuyers also have the flexibility to arrange a live video tour with a sales counselor. Pricing begins from the $210,000s.

For more information on KB Home, call 888-KB-HOMES or visit kbhome.com.

About KB Home

KB Home is one of the largest and most recognized homebuilders in the United States and has been building quality homes for over 60 years. Today, KB Home operates in 45 markets across eight states, serving a wide array of buyer groups. What sets us apart is how we give our customers the ability to personalize their homes from homesites and floor plans to cabinets and countertops, at a price that fits their budget. We are the first builder to make every home we build ENERGY STAR^® certified. In fact, we go beyond the EPA requirements by ensuring every ENERGY STAR certified KB home has been tested and verified by a third-party inspector to meet the EPA’s strict certification standards, which help to lower the cost of ownership and to make our new homes healthier and more comfortable than new ones without certification. We also work with our customers every step of the way, building strong personal relationships so they have a real partner in the homebuying process, and the experience is as simple and easy as possible. Learn more about how we build homes built on relationships by visiting kbhome.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005112/en/

Cara Kane, KB Home

321-299-6844

[email protected]

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Construction & Property Landscape Interior Design Building Systems Family Architecture Consumer Other Construction & Property Residential Building & Real Estate

MEDIA:

Logo

Photo

KB Home announces the grand opening of Willow Wood Place, a new-home community in North Houston priced from the $210,000s. (Photo: Business Wire)